Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Health Yuan Innovation and Quality Improvement: R&D investment accounted for nearly 10% in the first half of 2024, with multiple innovative drugs accelerating into the fast lane

Time Posted:2024-08-26 12:00

Since the beginning of this year, the innovative drug industry has seen a flurry of favorable policies. From comprehensive support programs to optimized clinical trial review and approval notices, and pilot programs in Beijing and Shanghai, these developments mark a transition in China's innovative drug industry from research and development investment to value realization. However, before these policy benefits are fully realized, a major challenge facing innovative pharmaceutical companies is how to achieve stable operations during this period of industry adjustment. HealthGen has submitted an answer centered on "innovation" and "stability".

Jiankangyuan's anti-influenza drug application for market listing

Time Posted:2024-08-12 17:35

On August 12, the CDE website showed that the marketing application for the influenza drug TG-1000 capsules of Jiankangyuan has been accepted.

2024 Top 100 Pharmaceutical Industry Comprehensive Competitiveness Ranking Released!

Time Posted:2024-08-10 20:00

On August 10th, at the West P Evening Banquet themed "Glory Beyond, Sparkling Stars", the Zhongkang Industry Research Institute released the 2024 Pharmaceutical Industry Comprehensive Competitiveness Index, and based on the index, generated the "2024 Pharmaceutical Industry Comprehensive Competitiveness Top 100 List." 100 benchmark enterprises received industry-wide accolades, composing a hymn of glory.

Applause! Lizhu has won the MSCI ESG Global AAA rating for consecutive years.

Time Posted:2024-08-02 12:40

Recently, MSCI (Morgan Stanley Capital International), a leading international index company, announced the latest annual ESG (Environmental, Social and Governance) rating results for Lizhu. In 2024, Lizhu's MSCI ESG rating has retained the highest global rating of AAA.

Dual-wheel drive, continuous dividend distribution, a leading company with tens of billions of assets increases investment in innovative drugs

Time Posted:2024-07-30 18:05

Driven by its dual-wheel strategy of "innovative drugs + high-end complex preparations", the well-known pharmaceutical company Health Yuan is continuing to lead in the inhalation preparation field. Moreover, since its listing in 2001, Health Yuan has maintained a stable dividend policy, having distributed cash dividends to shareholders 20 times, with a cumulative dividend amount exceeding 3.6 billion yuan.

Focus on chronic disease prevention and control: Healthy Yuan & Lizhu Chronic Disease Public Welfare Activities in Heishui County, Sichuan Province

Time Posted:2024-07-30 14:55

As an active promoter and practitioner of chronic disease public welfare undertakings, Health Yuan continues to promote the "Chronic Disease Public Welfare Supporting Rural Revitalization" action to various needy areas across the country. In May, Health Yuan & Lizhu Group, in collaboration with the Chengdu Xindu Community Development Foundation, Pengzhou Civil Affairs Bureau, Pengzhou's counterpart support team for Heishui County, and Heishui County Health and Health Bureau, implemented the chronic disease public welfare action in Heishui County.

< 1...789...55 >